Diaceutics (DXRX) Full Year 2022 Results presentation - April 2023

Diaceutics CFO, Nick Roberts & CIO Ryan Keeling present full year results for the period ended 31 December 2022, which shows a strong trading performance with continued momentum driving strategic investment into 2023.

Nick Roberts, CFO
00:16 - Introduction
01:58 - FY22 Highlights

Nick Roberts, CFO & Ryan Keeling, CIO
04:46 - Enterprise engagements
06:27 - Strategy Acceleration

Nick Roberts, CFO
12:26 - Revenue Growth
14:33 - P&L Statement

Nick Roberts, CFO & Ryan Keeling, CIO
17:06 - Growth and scale investement

Ryan Keeling, CIO
21:08 - DXRX Platform
28:24 - Outlook

Diaceutics provide the world's leading pharma and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.